易明医药: 关于董事减持股份计划期限届满暨实施结果的公告

Core Viewpoint - The company disclosed a share reduction plan by a major shareholder, Mr. Lic, who intends to reduce his holdings by up to 300,000 shares within a specified timeframe [1] Group 1: Shareholder Reduction Details - Mr. Lic's share reduction occurred from April 1 to April 12, 2025, with an average reduction price of 11.42 yuan per share, totaling 283,862 shares, which represents 0.15% of the company's total share capital [1] - Before the reduction, Mr. Lic held 1,215,447 shares (0.64% of total share capital), and after the reduction, he holds 931,585 shares (0.49% of total share capital) [1] - The shares reduced were sourced from Mr. Lic's holdings prior to the company's initial public offering and from equity incentive shares [1] Group 2: Compliance and Governance - The reduction plan complies with relevant regulations, including self-regulatory guidelines and stock exchange rules [1] - Mr. Lic has no outstanding commitments related to share changes that have not been disclosed and fulfilled [1] - The share reduction will not lead to a change in the company's control or affect its governance structure and ongoing operations [1]